MedPath

海南辉能药业有限公司

Ownership
-
Established
2015-03-13
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

4

NMPA:4

Drug Approvals

Flupentixol and Melitracen Tablets

Product Name
氟哌噻吨美利曲辛片
Approval Number
国药准字H20143390
Approval Date
Oct 18, 2024
NMPA

Flupentixol Dihydrochloride

Product Name
盐酸氟哌噻吨
Approval Number
国药准字H20140131
Approval Date
Oct 16, 2024
NMPA

Melitracen hydrochloride

Product Name
盐酸美利曲辛
Approval Number
国药准字H20140132
Approval Date
Oct 16, 2024
NMPA

Dapoxetine Hydrochloride Tablets

Product Name
盐酸达泊西汀片
Approval Number
国药准字H20233362
Approval Date
Mar 24, 2023
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.